Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has reported $16.1bn sales for the year 2010, an increase of 16% compared to 2009, and fourth quarter sales of $4.4bn.
Subscribe to our email newsletter
Annual non-GAAP net income and non-GAAP EPS was $4.1bn and $4.54, up 36% and 35%, respectively, compared to 2009.
For the fourth quarter, non-GAAP net income and non-GAAP EPS was $1.1bn and $1.25, up 35% and 33% respectively, compared with the same period in 2009.
Teva said the announced results show a record global in-market sales of Copaxone of $3.3bn in the year ended 2010, a 17% hike compared to 2009, and a record annual cash flow from operations of $4.1bn (a $3.4bn increase from 2009).
Teva president and CEO Shlomo Yanai said 2010 has been a great year for Teva, in which the company delivered record-breaking results across all its geographies while strengthening and expanding its global leadership.